ArticleNature genetics2025
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation.
Erratum issuedAbstract read
In one paragraph
Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future.NPJ cardiovascular health · 2026Review
- Immunological consequences of chemotherapy: implications for cancer immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases.Cancer · 2026Review
- Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.Leukemia · 2026Article
- Somatic mutations and clonal evolution in normal tissues and cancer development.Experimental & molecular medicine · 2026Review
- Modeling the evolutionary dynamics of clonal hematopoiesis.Nature genetics · 2026Review
- Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.Leukemia · 2026Article
- Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.HemaSphere · 2026Article
- The therapy-conditioned host: a state-transition framework for second primary cancer evolution.Frontiers in oncology · 2026Article
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
- CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.Research square · 2025Article
- How chemotherapy shapes hematopoietic stem cells.Nature genetics · 2025Article
Corrections and comments
- Erratum issued
- Update of
Authors and funding
44 authors.
Hidetaka UryuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Koichi SaekiTokyo University of Science, Division of Integrated Research, Research Institute for Biomedical Sciences, Noda, Japan.ORCID http://orcid.org/0000-0003-1886-8302
Hiroshi HaenoTokyo University of Science, Division of Integrated Research, Research Institute for Biomedical Sciences, Noda, Japan.ORCID http://orcid.org/0000-0002-6211-0649
Chiraag Deepak KapadiaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1805-8879
Ken FurudateDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1272-5490
Jyoti NangaliaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0001-7122-4608
Michael Spencer ChapmanWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID http://orcid.org/0000-0002-5320-8193
Linda ZhangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Jennifer PadillaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Li ZhaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joanne I HsuDepartment of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Chong ZhaoDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shujuan ChenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tomoyuki TanakaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zongrui LiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Satoko OgataDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0169-3959
Sarah HanacheDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui YangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9003-0390
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7103-373X
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0114-8384
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7621-377X
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5412-9860
Xingzhi SongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Erika ThompsonDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hongli TangDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Latasha LittleDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Curtis GumbsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert Z OrlowskiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5723-4129
Muzaffar QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kapil BhallaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5209-5126
Simona CollaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6583-8910
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1908-3307
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7829-5249
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0180-7124
Daisuke NakadaDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6010-7094
Gheath Al-AtrashDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7648-4377
Jeffery MolldremDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8663-2671
Elizabeth ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Margaret GoodellDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1111-2932
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3631-2482
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ktakahashi@mdanderson.org.ORCID http://orcid.org/0000-0002-8027-9659
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7MProject 3: Contribution of inflammation and DNA damaging factors to clonal expansion and malignant transformation in a community cohort of older adultsP01CA265748 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MARGARET A. GOODELL · 2022 to 2026
$13.6MDNMT3A in Development of Hematologic MalignanciesR01CA183252 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MARGARET A. GOODELL · 2014 to 2026
$7.1MPPM1D in Clonal Hematopoiesis and MalignanciesR01CA237291 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MARGARET A. GOODELL, Koichi Takahashi · 2019 to 2026
$3.7MNovel combination therapy for AML expressing mutant RUNX1R01CA262636 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHALLA, KAPIL, DINARDO, COURTNEY · 2021 to 2024
$2.1MNCI NIH HHS P01 CA265748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA183252NCI NIH HHS R01 CA237291NCI NIH HHS R01 CA262636U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA265748U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA237291U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA262636
Abstract
The impact of exogenous stressors, such as cancer chemotherapies, on the genomic integrity and clonal dynamics of normal hematopoiesis is not well defined. We conducted whole-genome sequencing on 1,276 single-cell-derived hematopoietic stem and progenitor cell (HSPC) colonies from ten patients with multiple myeloma treated with chemotherapies and six normal donors. Melphalan treatment significantly increased the mutational burden, producing a distinctive mutation signature, whereas other chemotherapeutic agents had minimal effects. Consequently, the clonal diversity and architecture of post-treatment HSPCs resemble those observed in normal elderly individuals, particularly through the progression of oligoclonal hematopoiesis, thereby suggesting that chemotherapy accelerates clonal aging. Integrated phylogenetic analysis of matched therapy-related myeloid neoplasm samples traced their clonal origin to a single-HSPC clone among multiple competing clones, supporting a model of oligoclonal to monoclonal transformation. These findings underscore the need for further systematic research on the long-term hematological consequences of cancer chemotherapy.
Indexed as
Clonal EvolutionHematopoietic Stem CellsHematopoietic Stem Cell TransplantationMultiple MyelomaAgedFemaleHumansMaleMelphalanMiddle AgedMutationPhylogenyTransplantation, AutologousWhole Genome SequencingMelphalan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.